DOCSLIB.ORG

Diagnosis and Management of Glycogen Storage Diseases Type VI and IX: a Clinical Practice Resource of the American College of Medical Genetics and Genomics (ACMG)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diagnosis and Management of Glycogen Storage Diseases Type VI and IX: a Clinical Practice Resource of the American College of Medical Genetics and Genomics (ACMG) © American College of Medical Genetics and Genomics ACMG PRACTICE RESOURCE Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) A full list of authors and affiliations appears at the end of the paper. Disclaimer This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessarily assure a successful medical outcome. This practice resource should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinician should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure or test, whether or not it is in conformance with this practice resource. Clinicians also are advised to take notice of the date this practice resource was adopted, and to consider other medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures. Purpose: Glycogen storage disease (GSD) types VI and IX are rare Results: This management guideline specifically addresses evalua- diseases of variable clinical severity affecting primarily the liver. tion and diagnosis across multiple organ systems involved in GSDs GSD VI is caused by deficient activity of hepatic glycogen PYGL VI and IX. Conditions to consider in a differential diagnosis phosphorylase, an enzyme encoded by the gene. GSD IX is stemming from presenting features and diagnostic algorithms are caused by deficient activity of phosphorylase kinase (PhK), the discussed. Aspects of diagnostic evaluation and nutritional and enzyme subunits of which are encoded by various genes: ɑ (PHKA1, PHKA2 β PHKB ɣ PHKG1 PHKG2 δ CALM1 CALM2 medical management, including care coordination, genetic counsel- ), ( ), ( , ), and ( , , ing, and prenatal diagnosis are addressed. CALM3). Glycogen storage disease types VI and IX have a wide spectrum of clinical manifestations and often cannot be distin- Conclusion: A guideline that will facilitate the accurate diagnosis guished from each other, or from other liver GSDs, on clinical and optimal management of patients with GSDs VI and IX was presentation alone. Individuals with GSDs VI and IX can present developed. This guideline will help health-care providers recognize with hepatomegaly with elevated serum transaminases, ketotic patients with GSDs VI and IX, expedite diagnosis, and minimize hypoglycemia, hyperlipidemia, and poor growth. This guideline for adverse sequelae from delayed diagnosis and inappropriate the management of GSDs VI and IX was developed as an management. It will also help identify gaps in scientific knowledge educational resource for health-care providers to facilitate prompt that exist today and suggest future studies. and accurate diagnosis and appropriate management of patients. Genetics in Medicine Methods: A national group of experts in various aspects of GSDs VI (2019) https://doi.org/10.1038/s41436-018-0364-2 and IX met to review the limited evidence base from the scientific literature and provided their expert opinions. Consensus was Keywords: glycogen storage diseases; glycogen storage disease developed in each area of diagnosis, treatment, and management. type VI; glycogen storage disease type IX; diagnostic guidelines; Evidence bases for these rare disorders are largely based on expert management guidelines opinion, particularly when targeted therapeutics that have to clear the US Food and Drug Administration (FDA) remain unavailable. PURPOSE present in other tissues. Glycogen is a polymer made up of This guideline is intended as an educational resource. It highly branched chains of glucose molecules. In the liver, highlights current practices and therapeutic approaches to the glycogen acts as a glucose reserve for maintenance of blood diagnosis and management of the multiple complications of glucose levels, especially in the fasting state. A low blood glycogen storage disease (GSD) types VI and IX. glucose level activates a series of enzymatic reactions that break down liver glycogen into glucose. The regulation of GENERAL BACKGROUND glycogen breakdown involves activation of adenylate cyclase Overview by the hormones glucagon and epinephrine, which increases Glycogen is the main storage form of carbohydrate in the cytosolic level of cAMP. The increased level of cAMP humans. It is most abundant in liver and muscle but is also activates cAMP-dependent protein kinase which, in turn, Correspondence: Michael S. Watson ([email protected]) The Board of Directors of the American College of Medical Genetics and Genomics approved this clinical practice resource on 27 August 2018. Submitted 24 September 2018; accepted: 15 October 2018 GENETICS in MEDICINE | Volume 0 | Number 0 | Month 1 ACMG PRACTICE RESOURCE KISHNANI et al activates phosphorylase kinase (PhK). PhK activates the next different genes: PHKG1 (OMIM *172470) in muscle and enzyme in the cascade, phosphorylase. Phosphorylase cata- PHKG2 (OMIM *172471) in liver. There is only one gene lyzes the sequential cleavage of the terminal units from the encoding the β-subunit, PHKB (OMIM *172490), but it is glycogen chains, liberating glucose-1-phosphate, which is then differentially spliced in different tissues including muscle, converted to glucose-6-phosphate.1 liver, and brain.13,14 The δ-subunit of PhK, calmodulin, is At least three human glycogen phosphorylases exist, each of encoded by three different genes—CALM1 (OMIM *114180), which is preferentially expressed in a different tissue; muscle, CALM2 (OMIM *114182), and CALM3 (OMIM *114183)— liver, and brain isoforms have been identified.1,2 GSD VI which are ubiquitously expressed and involved in other (OMIM 232700) is the result of a deficiency of liver glycogen cellular processes as well. Pathogenic variants in the PHKA2, phosphorylase, which is encoded by the PYGL (OMIM PHKB, and PHKG2 genes have been identified in patients *613741) gene located on chromosome 14q21-q22.3 PYGL is with liver GSD IX. the only gene known to be associated with GSD VI. Deficiency of muscle glycogen phosphorylase causes GSD V History (OMIM 232600),4 also known as McArdle disease, and will Glycogen storage disease type VI (Hers disease) (OMIM not be discussed here. 232700) (GSD VI) was reported by Henry-Gery Hers in Glycogen storage disease type IX, liver form, (OMIM 1959.15 Hers described three patients with hepatomegaly, mild 306000) (GSD IX) is often clinically indistinguishable from hypoglycemia, an increased glycogen content and deficient GSD VI. It results from deficiency of liver phosphorylase activity of glycogen phosphorylase in the liver. kinase (PhK). Isolated muscle PhK deficiency that is caused The first reported patient with liver PhK deficiency was by pathogenic variants in PHKA1 and has also been known as described by Hug et al. in 1966.16 The patient was a female – GSD IXd, has also been described5 11 but will not be discussed and the disorder was believed to be inherited in an autosomal 1234567890():,; in further detail here. PhK is a protein kinase that recessive manner. Later in the 1960s, patients with X-linked phosphorylates the inactive form of glycogen phosphorylase, inheritance of hepatic PhK deficiency were described.17 In phosphorylase b, to produce the active form, phosphorylase a. some early publications, these patients were described as PhK is a heterotetramer composed of four copies each of α, β, having a subtype of GSD VI, because they had low γ, and δ subunits.12 The γ subunit contains the catalytic site. phosphorylase activity in addition to PhK deficiency.18,19 Its activity is regulated by the phosphorylation state of the The term GSD IX, first designated by Hug et al.,20 was regulatory α and β subunits, and by the δ subunit ultimately used to describe patients with primary PhK (calmodulin) via calcium levels.12 PhK has a wide tissue deficiency, regardless of the inheritance pattern. distribution with multiple tissue-specific isoforms generated by the expression and differential splicing of the various PhK Nomenclature subunit genes12 (Tables 1 and 2). The α-subunit is encoded by In older literature, GSD VI has sometimes been referred to as the PHKA1 (OMIM *311870) gene in muscle and by the type VIII and IX, and GSD IX has been called GSD VIa and PHKA2 (OMIM *300798) gene in liver. There are also muscle VIII.21 To standardize the nomenclature in this guideline and liver isoforms of the γ-subunit, each also encoded by paper, GSD VI will be used here to describe liver glycogen phosphorylase deficiency, and GSD IX will refer to PhK Table 1 Phosphorylase kinase (PhK) subunit genes known to deficiency. PhK deficiency can be divided into two main types cause PhK deficiency in which symptoms primarily affect liver or muscle. Liver PhK Gene PhK Location Inheritance Tissue/organ deficiency (liver GSD IX) can be further subclassified subunit primarily affected according to the gene involved. PHKA2-related GSD IX is PHKA2 PHKA1 α Xq13.1 X-linked Muscle caused by changes
Load more

Recommended publications
  • Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”
    Supplemental information to Mammadova-Bach et al., “Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinogenesis” Supplemental material and methods Cloning of the villin-LMα1 vector The plasmid pBS-villin-promoter containing the 3.5 Kb of the murine villin promoter, the first non coding exon, 5.5 kb of the first intron and 15 nucleotides of the second villin exon, was generated by S. Robine (Institut Curie, Paris, France). The EcoRI site in the multi cloning site was destroyed by fill in ligation with T4 polymerase according to the manufacturer`s instructions (New England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Site directed mutagenesis (GeneEditor in vitro Site-Directed Mutagenesis system, Promega, Charbonnières-les-Bains, France) was then used to introduce a BsiWI site before the start codon of the villin coding sequence using the 5’ phosphorylated primer: 5’CCTTCTCCTCTAGGCTCGCGTACGATGACGTCGGACTTGCGG3’. A double strand annealed oligonucleotide, 5’GGCCGGACGCGTGAATTCGTCGACGC3’ and 5’GGCCGCGTCGACGAATTCACGC GTCC3’ containing restriction site for MluI, EcoRI and SalI were inserted in the NotI site (present in the multi cloning site), generating the plasmid pBS-villin-promoter-MES. The SV40 polyA region of the pEGFP plasmid (Clontech, Ozyme, Saint Quentin Yvelines, France) was amplified by PCR using primers 5’GGCGCCTCTAGATCATAATCAGCCATA3’ and 5’GGCGCCCTTAAGATACATTGATGAGTT3’ before subcloning into the pGEMTeasy vector (Promega, Charbonnières-les-Bains, France). After EcoRI digestion, the SV40 polyA fragment was purified with the NucleoSpin Extract II kit (Machery-Nagel, Hoerdt, France) and then subcloned into the EcoRI site of the plasmid pBS-villin-promoter-MES. Site directed mutagenesis was used to introduce a BsiWI site (5’ phosphorylated AGCGCAGGGAGCGGCGGCCGTACGATGCGCGGCAGCGGCACG3’) before the initiation codon and a MluI site (5’ phosphorylated 1 CCCGGGCCTGAGCCCTAAACGCGTGCCAGCCTCTGCCCTTGG3’) after the stop codon in the full length cDNA coding for the mouse LMα1 in the pCIS vector (kindly provided by P.
    [Show full text]
  • Supplementary Table 1
    Table S1. List of Genes Differentially Expressed in YB-1 siRNA-Transfected MCF-7 Cells Unigene Accession Symbol Description Mean fold change Hs.17466 NM_004585 RARRES3 retinoic acid receptor responder (tazarotene induced) 3 3.57 Hs.64746 NM_004669 CLIC3 chloride intracellular channel 3 3.33 Hs.516155 NM_001747 CAPG capping protein (actin filament), gelsolin-like 2.88 Hs.926 NM_002463 MX2 myxovirus (influenza virus) resistance 2 (mouse) 2.72 Hs.643494 NM_005410 SEPP1 selenoprotein P, plasma, 1 2.70 Hs.267038 BC017500 POF1B premature ovarian failure 1B 2.67 Hs.20961 U63917 GPR30 G protein- coupled receptor 30 2532.53 Hs.199877 BE645967 CPNE4 copine IV 2.49 Hs.632177 NM_017458 MVP major vault protein 2.48 Hs.528836 AA005023 NOD27 nucleotide-binding oligomerization domains 27 2.43 Hs.360940 AL589866 dJ222E13.1 kraken-like 2.40 Hs.515575 AI743780 PLAC2 placenta-specific 2 2.37 Hs.25674 AI827820 MBD2 methyl-CpG binding domain protein 2 2.36 Hs.12229 AA149594 TIEG2 TGFB inducible early growth response 2 2.33 Hs.482730 AA053711 EDIL3 EGF-like repeats and discoidin I-like domains 3 2.32 Hs. 370771 NM_000389 CDKN1A cyclin- depen dent kinase in hibitor 1A (p 21, Cip 1) 2282.28 Hs.469175 AI341537 JFC1 NADPH oxidase-related, C2 domain-containing protein 2.28 Hs.514821 AF043341 CCL5 chemokine (C-C motif) ligand 5 2.27 Hs.591292 NM_023915 GPR87 G protein-coupled receptor 87 2.26 Hs.500483 NM_001613 ACTA2 actin, alpha 2, smooth muscle, aorta 2.24 Hs.632824 NM_006729 DIAPH2 diaphanous homolog 2 (Drosophila) 2.22 Hs.369430 NM_000919 PAM peptidylglycine
    [Show full text]
  • PYGL Rabbit Polyclonal Antibody
    PYGL Rabbit Polyclonal Antibody CAB6710 Product Information Protein Background Size: This gene encodes a homodimeric protein that catalyses the cleavage of alpha-1, 4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores. This protein switches from 20uL, 50uL, 100uL, 200uL inactive phosphorylase B to active phosphorylase A by phosphorylation of serine residue 15. Activity of this enzyme is further regulated by multiple allosteric effectors and hormonal Observed MW: controls. Humans have three glycogen phosphorylase genes that encode distinct isozymes that 110kDa are primarily expressed in liver, brain and muscle, respectively. The liver isozyme serves the glycemic demands of the body in general while the brain and muscle isozymes supply just Calculated MW: those tissues. In glycogen storage disease type VI, also known as Hers disease, mutations in liver glycogen phosphorylase inhibit the conversion of glycogen to glucose and results in 93kDa/97kDa moderate hypoglycemia, mild ketosis, growth retardation and hepatomegaly. Alternative splicing results in multiple transcript variants encoding different isoforms. Applications: WB IF IP Immunogen information Reactivity: Gene ID: 5836 Human, Mouse, Rat Uniprot P06737 Antibody Information Recommended dilutions: Synonyms: WB 1:500 - 1:2000 IF 1:50 - PYGL; GSD6 1:200 IP 1:50 - 1:200 Source: Rabbit Immunogen: Recombinant fusion protein containing a sequence corresponding Isotype: to amino acids 1-280 of human PYGL (NP_002854.3). IgG Storage: Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. Purification: Affinity purification Copyright © 2021 Assay Genie [email protected] www.assaygenie.com Product Images Western blot analysis of extracts of various cell lines, using PYGL antibody (CAB6710) at 1:1000 dilution.
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • Defective Galactose Oxidation in a Patient with Glycogen Storage Disease and Fanconi Syndrome
    Pediatr. Res. 17: 157-161 (1983) Defective Galactose Oxidation in a Patient with Glycogen Storage Disease and Fanconi Syndrome M. BRIVET,"" N. MOATTI, A. CORRIAT, A. LEMONNIER, AND M. ODIEVRE Laboratoire Central de Biochimie du Centre Hospitalier de Bichre, 94270 Kremlin-Bicetre, France [M. B., A. C.]; Faculte des Sciences Pharmaceutiques et Biologiques de I'Universite Paris-Sud, 92290 Chatenay-Malabry, France [N. M., A. L.]; and Faculte de Midecine de I'Universiti Paris-Sud et Unite de Recherches d'Hepatologie Infantile, INSERM U 56, 94270 Kremlin-Bicetre. France [M. 0.1 Summary The patient's diet was supplemented with 25-OH-cholecalci- ferol, phosphorus, calcium, and bicarbonate. With this treatment, Carbohydrate metabolism was studied in a child with atypical the serum phosphate concentration increased, but remained be- glycogen storage disease and Fanconi syndrome. Massive gluco- tween 0.8 and 1.0 mmole/liter, whereas the plasma carbon dioxide suria, partial resistance to glucagon and abnormal responses to level returned to normal (18-22 mmole/liter). Rickets was only carbohydrate loads, mainly in the form of major impairment of partially controlled. galactose utilization were found, as reported in previous cases. Increased blood lactate to pyruvate ratios, observed in a few cases of idiopathic Fanconi syndrome, were not present. [l-14ClGalac- METHODS tose oxidation was normal in erythrocytes, but reduced in fresh All studies of the patient and of the subjects who served as minced liver tissue, despite normal activities of hepatic galactoki- controls were undertaken after obtaining parental or personal nase, uridyltransferase, and UDP-glucose 4epirnerase in hornog- consent. enates of frozen liver.
    [Show full text]
  • Improvement of the Nutritional Management of Glycogen Storage Disease Type I
    1 Improvement of the nutritional management of glycogen storage disease type I Kaustuv Bhattacharya Presented for the degree of MD (res) at University College London 2 “The roots below the earth claim no rewards for making the branches fruitful” Sir Rabrindranath Tagore Stray Birds (1917) Acknowledgements Whilst this thesis is my own work, it is the product of several helpful discussions with many people around the world. It was conducted under the supervision of Philip Lee who, since completion of the data collection, faced bigger personal challenges than he could have imagined. I hope that this work is a fitting conclusion to one strategic direction, of some of his research, which I hope he can be proud of. I am very grateful for his help. Peter Clayton has been a source of inspiration throughout my “metabolic” career and his guidance throughout this process has been very gratefully received. I appreciate the tolerance of my other colleagues at Queen Square and Great Ormond Street Hospital that have accommodated in different ways. The dietetic experience of Maggie Lilburn has been invaluable to this work. Simon Eaton has helped tremendously with performing the assays in chapter 5. I would also like to thank, David Morley, Amy Cole, Martin Christian, and Bridget Wilcken for their constructive thoughts. None of this work would have been possible without the Murphy family’s generous support. I thank the Dromintee Trust for keeping me in worthwhile employment. I would like to thank the patients who volunteered and gave me so much of their time. The Association for Glycogen Storage Disease (UK), Glycologic Ltd and Vitaflo Ltd have also sponsored these trials and hopefully facilitated a better experience for patients.
    [Show full text]
  • General Nutrition Guidelines for Glycogen Storage Disease Type III
    General Nutrition Guidelines For Glycogen Storage Disease Type III Glycogen Storage Disease Type III (GSDIII) is a genetic metabolic disorder which causes the inability to break down glycogen to glucose. Glycogen is a stored form of sugar in the body. Glucose (sugar) is the main source of fuel for the body and brain. GSD IIIa causes the inability of the liver and muscles to breakdown glycogen to glucose. GSD IIIb causes the inability of the liver to breakdown glycogen to glucose. As a result of the inability to breakdown glycogen, patients with GSDIII are at risk for low blood sugars (hypoglycemia) during periods of fasting. Patients with GSDIIIa also do not have the ability to access glycogen in their muscles as well. The lack of glycogen access in the muscles causes muscle damage as the muscle do not have a fuel to aid them in working. The following is a recommended general nutrition guideline for those with GSDIII to help maximize blood sugar control, nutrition, energy, and hopefully minimize muscle damage for those with GSDIIIa. Protein What is protein? Protein is a macronutrient (like carbohydrate and fat) and is required for proper growth and development. In GSDIII, the most important role that protein serves is a way for the body to make glucose since those with GSDIII do not have access to stored sugars (glycogen). Protein also serves as the building blocks for our cells, is also necessary to make antibodies which help our bodies fight off illnesses, make up hormones, enzymes, and even our DNA. With GSD type III, it is very important to make sure you are getting all the protein that your body needs.
    [Show full text]
  • Phosphoproteomics of Retinoblastoma: a Pilot Study Identifies Aberrant Kinases
    molecules Article Phosphoproteomics of Retinoblastoma: A Pilot Study Identifies Aberrant Kinases Lakshmi Dhevi Nagarajha Selvan 1,†, Ravikanth Danda 1,2,†, Anil K. Madugundu 3 ID , Vinuth N. Puttamallesh 3, Gajanan J. Sathe 3,4, Uma Maheswari Krishnan 2, Vikas Khetan 5, Pukhraj Rishi 5, Thottethodi Subrahmanya Keshava Prasad 3,6 ID , Akhilesh Pandey 3,7,8, Subramanian Krishnakumar 1, Harsha Gowda 3,* and Sailaja V. Elchuri 9,* 1 L&T Opthalmic Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu 600 006, India; [email protected] (L.D.N.S.); [email protected] (R.D.); [email protected] (S.K.) 2 Centre for Nanotechnology and Advanced Biomaterials, Shanmugha Arts, Science, Technology and Research Academy University, Tanjore, Tamil Nadu 613 401, India; [email protected] 3 Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka 560 066, India; [email protected] (A.K.M.); [email protected] (V.N.P.); [email protected] (G.J.S.); [email protected] (T.S.K.P.); [email protected] (A.P.) 4 Manipal Academy of Higher Education (MAHE), Manipal, Karnataka 576 104, India 5 Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu 600 006, India; [email protected] (V.K.); [email protected] (P.R.) 6 Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka 575 108, India 7 McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 8 Departments of Biological Chemistry, Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 9 Department of Nanotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu 600 006, India * Correspondence: [email protected] (H.G.); [email protected] (S.V.E.); Tel.: +91-80-28416140 (H.G.); +91-44-28271616 (S.V.E.) † These authors contributed equally to this work.
    [Show full text]
  • Molecular Diagnosis of Glycogen Storage Disease and Disorders with Overlapping Clinical Symptoms by Massive Parallel Sequencing
    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Molecular diagnosis of glycogen storage disease and disorders with overlapping clinical symptoms by massive parallel sequencing Ana I Vega, PhD1,2,3, Celia Medrano, BSc1,2,3, Rosa Navarrete, BSc1,2,3, Lourdes R Desviat, PhD1,2,3, Begoña Merinero, PhD1,2,3, Pilar Rodríguez-Pombo, PhD1,2,3, Isidro Vitoria, MD, PhD4, Magdalena Ugarte, PhD1,2,3, Celia Pérez-Cerdá, PhD1,2,3 and Belen Pérez, PhD1,2,3 Purpose: Glycogen storage disease (GSD) is an umbrella term for a Results: Pathogenic mutations were detected in 23 patients. group of genetic disorders that involve the abnormal metabolism of ­Twenty-two mutations were recognized (mostly loss-of-function glycogen; to date, 23 types of GSD have been identified. The nonspe- mutations), including 11 that were novel in GSD-associated genes. In cific clinical presentation of GSD and the lack of specific biomarkers addition, CES detected five patients with mutations in ALDOB, LIPA, mean that Sanger sequencing is now widely relied on for making a NKX2-5, CPT2, or ANO5. Although these genes are not involved in diagnosis. However, this gene-by-gene sequencing technique is both GSD, they are associated with overlapping phenotypic characteristics laborious and costly, which is a consequence of the number of genes such as hepatic, muscular, and cardiac dysfunction. to be sequenced and the large size of some genes. Conclusions: These results show that next-generation sequenc- ing, in combination with the detection of biochemical and clinical Methods: This work reports the use of massive parallel sequencing hallmarks, provides an accurate, high-throughput means of making to diagnose patients at our laboratory in Spain using either a cus- genetic diagnoses of GSD and related diseases.
    [Show full text]
  • Six Glycolysis-Related Genes As Prognostic Risk Markers Can Predict the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma
    Hindawi BioMed Research International Volume 2021, Article ID 8824195, 13 pages https://doi.org/10.1155/2021/8824195 Research Article Six Glycolysis-Related Genes as Prognostic Risk Markers Can Predict the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma LangXiong Chen ,1,2 XiaoSong He,1,2 ShiJiang Yi,1,2 GuanCheng Liu,1,2 Yi Liu,1,2 and YueFu Ling 1,2 1Otolaryngology & Head and Neck Surgery, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China 2The Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China Correspondence should be addressed to YueFu Ling; [email protected] Received 19 September 2020; Revised 10 January 2021; Accepted 15 January 2021; Published 10 February 2021 Academic Editor: R. K. Tripathy Copyright © 2021 LangXiong Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Head and neck squamous cell carcinoma (HNSCC) is one of the worst-prognosis malignant tumors. This study used bioinformatic analysis of the transcriptome sequencing data of HNSCC and the patients’ survival and clinical data to construct a prediction signature of glycolysis-related genes as the prognostic risk markers. Methods. Gene expression profile data about HNSCC tissues (n = 498) and normal tissues in the head and neck (n =44) were got from The Cancer Genome Atlas (TCGA), as well as patients’ survival and clinical data. Then, we obtained core genes; their expression in head and neck squamous cell carcinoma tissues is significantly different from that in normal head and neck tissues.
    [Show full text]
  • 6 the Glycogen Storage Diseases and Related Disorders
    6 The Glycogen Storage Diseases and Related Disorders G. Peter A. Smit, Jan Peter Rake, Hasan O. Akman, Salvatore DiMauro 6.1 The Liver Glycogenoses – 103 6.1.1 Glycogen Storage Disease Type I (Glucose-6-Phosphatase or Translocase Deficiency) – 103 6.1.2 Glycogen Storage Disease Type III (Debranching Enzyme Deficiency) – 108 6.1.3 Glycogen Storage Disease Type IV (Branching Enzyme Deficiency) – 109 6.1.4 Glycogen Storage Disease Type VI (Glycogen Phosphorylase Deficiency) – 111 6.1.5 Glycogen Storage Disease Type IX (Phosphorylase Kinase Deficiency) – 111 6.1.6 Glycogen Storage Disease Type 0 (Glycogen Synthase Deficiency) – 112 6.2 The Muscle Glycogenoses – 112 6.2.1 Glycogen Storage Disease Type V (Myophosphorylase Deficiency) – 113 6.2.2 Glycogen Storage Disease Type VII (Phosphofructokinase Deficiency) – 113 6.2.3 Phosphoglycerate Kinase Deficiency – 114 6.2.4 Glycogen Storage Disease Type X (Phosphoglycerate Mutase Deficiency) – 114 6.2.5 Glycogen Storage Disease Type XII (Aldolase A Deficiency) – 114 6.2.6 Glycogen Storage Disease Type XIII (E-Enolase Deficiency) – 115 6.2.7 Glycogen Storage Disease Type XI (Lactate Dehydrogenase Deficiency) – 115 6.2.8 Muscle Glycogen Storage Disease Type 0 (Glycogen Synthase Deficiency) – 115 6.3 The Generalized Glycogenoses and Related Disorders – 115 6.3.1 Glycogen Storage Disease Type II (Acid Maltase Deficiency) – 115 6.3.2 Danon Disease – 116 6.3.3 Lafora Disease – 116 References – 116 102 Chapter 6 · The Glycogen Storage Diseases and Related Disorders Glycogen Metabolism Glycogen is a macromolecule composed of glucose viding glucose and glycolytic intermediates (. Fig. 6.1). units.
    [Show full text]
  • Glycogen Storage Diseases Are Genetic Deficiencies That Result in the Storage of Abnormal Amounts of Glycogen in the Body
    UNDERSTANDING GLYCOGEN STORAGE DISEASE What is Glycogen Storage Disease? Glycogen storage diseases are genetic deficiencies that result in the storage of abnormal amounts of glycogen in the body. About 1 out of 100 000 babies are born with glycogen storage diseases each year in Canada. There are 5 different types of these diseases depending on the enzyme missing, however, only type 1a will be described here. All people who are born with GSD have one thing in common. They are unable to properly metabolize or break down glycogen, the storage form of sugar in the body. The food we eat is usually used for growth, tissue repair and energy. The body stores what it does not use. Excess sugar, or glucose, is stored as glycogen in the liver and muscle tissue. Between meals and during sleep (i.e. periods of fasting), or during exercise, the body breaks down glycogen and uses the stored sugar for energy. Due to an enzyme deficiency, people with GSD have the ability to store sugar as glycogen but are unable to use these stores to provide the body with energy during fasting or exercise. Think of a pantry where extra food is stored. In times of need, the pantry door can be opened and food can be accessed. In glycogen storage disease, food can be placed in the pantry for storage, but can’t be accessed in times of need. The pantry door is locked. Food can be pushed through a slot in the door but the door cannot be opened to get the food out.
    [Show full text]